Results 21 to 30 of about 2,285,787 (260)

Cytokine Release Syndrome After Modified CAR-NK Therapy in an Advanced Non-small Cell Lung Cancer Patient: A Case Report

Cell Transplantation, 2022
Use of chimeric antigen receptors (CARs), as an immune cell therapy, has generated excellent clinical outcomes against hematologic tumors in recent years.
Xiaodi Zhang, Yuying Guo, Yinghua Ji, Yan Gao, Min Zhang, Yanting Liu, Wuling Zhu, Ping Lu   +7 more
doaj   +1 more source

CAR-T Therapy in Lymphoma Patients With Coexisting Cardiomyopathy or Cardiac Lymphomatous Involvement

JACC: Case Reports, 2023
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the management of aggressive hematologic malignancies. However, its role in patients with lymphoma and cardiac metastasis or cardiomyopathy remains undefined due to potentially life ...
Choon Ta Ng, MBBS, Hilda M. Gonzalez Bonilla, MD, Ian Chang, MD, M. Tun Aung, MD, Jennifer J. Gile, MD, Naveen L. Pereira, MD, Jose C. Villasboas Bisneto, MD, Patrick B. Johnston, MD, Hector R. Villarraga, MD, Martin G. Rodriguez-Porcel, MD, Grace Lin, MD, Yi Lin, MD, PhD, Joerg Herrmann, MD   +12 more
doaj   +1 more source

Chimeric Antigen Receptor T-cell Therapy (CAR T)

, 2022
This is an adoptive T-cell therapy which uses engineered T-cell. In which they are obtain from a patient’s immune system by its own to attack cancer cells through targeting proteins expressed on the cellular membrane, that process involves obtaining T ...
Dr. Vachaspati Narayan, Dr. Mahender Miland, Dr. Kritika Gahlot, Dr. Mukul Purva
core   +1 more source

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges

Acta Pharmaceutica Sinica B, 2018
Chimeric antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy where T lymphocytes are engineered with synthetic receptors known as chimeric antigen receptors (CAR).
Zijun Zhao, Yu Chen, Ngiambudulu M. Francisco, Yuanqing Zhang, Minhao Wu   +4 more
doaj   +1 more source

Natural killer cell immunotherapy in glioblastoma

Discover Oncology, 2022
Glioblastoma (GBM) is one of the most difficult cancers to treat because GBM has the high therapeutic resistance. Recently, immunotherapies for GBM have been used instead of conventional treatments.
Hamed Hosseinalizadeh, Mehryar Habibi Roudkenar, Amaneh Mohammadi Roushandeh, Yoshikazu Kuwahara, Kazuo Tomita, Tomoaki Sato   +5 more
doaj   +1 more source

Chimeric Antigen Receptor (CAR)-T Cell Therapy [PDF]

, 2018
Article信州医学雑誌 66(6): 425-433(2018)journal ...
齋藤, 章治, 中沢, 洋三
core   +1 more source

Generation of redirected engineered human chimeric antigen receptor (CAR) T cells

, 2022
Chimeric antigen receptor (CAR) T cell therapy that involves genetic engineering a patient's own immune cells with antigen-specific receptors has shown remarkable efficacy in blood cancer treatment.
Höpken, U.E., Bunse, M.
core   +1 more source

Chimeric antigen receptors (CARs) from bench-to-bedside

Immunology Letters, 2013
Chimeric antigen receptors (CARs) combine the antigen specificity of an antibody with the biologic properties of T lymphocytes. While the concept has been developed more than 20 years ago, only in recent years the clinical application of this approach has produced remarkable objective clinical responses.
Barbara, Savoldo, Gianpietro, Dotti
openaire   +3 more sources

Chimeric Antigen Receptor (CAR) therapy for multiple myeloma [PDF]

British Journal of Haematology, 2016
SummaryThe introduction of chimeric antigen receptor (CAR)‐modified T cells has revolutionized immunotherapy and cancer treatment as a whole. However, so far, clinical efficacy has only been demonstrated for CD19‐positive B cell lymphomas. For Multiple Myeloma (MM), the second most common haematological malignancy, there are currently no clinical ...
Djordje, Atanackovic, Sabarinath V, Radhakrishnan, Neelam, Bhardwaj, Tim, Luetkens   +3 more
openaire   +2 more sources

Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma

Nature Communications, 2021
Antibodies targeting a tumor antigen, GD2, show some efficacy for neuroblastoma but induce severe neuropathic pain and peripheral neuropathy. Here the authors design a gated chimeric antigen receptor (CAR), using GD2 as the gate and another tumor antigen,
Babak Moghimi, Sakunthala Muthugounder, Samy Jambon, Rachelle Tibbetts, Long Hung, Hamid Bassiri, Michael D. Hogarty, David M. Barrett, Hiroyuki Shimada, Shahab Asgharzadeh   +9 more
doaj   +1 more source